>) is committed to delivering intelligent
devices and biologics that help monitor, diagnose and treat heart failure
and cardiovascular diseases. Its goals are to improve a patient's quality
of life and reduce health care costs and hospitalizations. Specific to
biotechnology, Bioheart is focused on the discovery, development and,
subject to regulatory approval, commercialization of autologous cell
therapies for the treatment of chronic and acute heart damage. Its lead
product candidate, MyoCell(R), is an innovative clinical muscle-derived
stem cell therapy designed to populate regions of scar tissue within a
patient's heart with new living cells for the purpose of improving cardiac
function in chronic heart failure patients. The Company's pipeline includes
multiple product candidates for the treatment of heart damage, including
Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem
cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy
utilizing autologous cells that are genetically modified to express
additional potentially therapeutic growth proteins. For more information on
Bioheart, visit
http://www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Forward Looking Statements:
Except for historical matters contained herein, statements made in this
press release are forward-looking and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Without
limiting the generality of the foregoing, words such as "may", "will",
"to", "plan", "expect", "believe", "anticipate", "intend", "could",
"would", "estimate", or "continue" or the negative other variations thereof
or comparable terminology are intended to identify forward-looking
statements.
Investors and others are cautioned that a variety of factors, including
certain risks, may affect our business and cause actual results to diff
'/>"/>
SOURCE Bioheart, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 20082.
Bioheart, Inc. Announces Financial Results for First Quarter 20083.
Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements4.
Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 20085.
Bioheart, Inc. to Transfer to Nasdaq Capital Market6.
Bioheart, Inc., Added to Russell Microcap Index7.
Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer8.
Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients9.
BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC10.
The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh11.
Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures